Life Sciences Leader Jill DeSimone and Private Equity Executive Neeraj Bharadwaj Join Indegene’s Board

Princeton / Bengaluru, January 29, 2026: Indegene today announced that Jill DeSimone, a widely respected global life sciences leader, and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene’s Board of Directors.

These appointments strengthen Board oversight through complementary perspectives on long-term value creation, governance, and technology-led life sciences modernization, reinforcing Indegene’s commitment to the highest standards of corporate governance.

Jill brings over four decades of life sciences leadership, with hands-on experience building and leading large commercial and medical organizations. She has held senior leadership roles at leading biopharma companies, including President of U.S. Oncology at Merck, where she led major businesses and product franchises across global markets. She led the launch of Keytruda, Merck’s first true oncology product. Jill has also held leadership roles at Teva and Bristol Myers Squibb. She currently serves on the Boards of several public and private biotech companies and brings a valuable set of experiences to Indegene.

Neeraj brings extensive experience in private equity, capital allocation, and portfolio value creation. He is currently a Senior Advisor with Carlyle Asia and previously held leadership roles at Accel Partners’ growth investing operations in India and Apax Partners. He has worked closely with boards and management teams to support disciplined growth, inorganic expansion, and sustained value creation across scaled businesses, including healthcare and technology-enabled services.

Welcoming Jill and Neeraj to Indegene’s Board, Manish Gupta, Chairman and CEO, Indegene, said, “Strong corporate governance has always been integral to Indegene’s DNA. Jill and Neeraj join our Board as highly respected leaders whose experience aligns closely with Indegene’s strategy and operating model. Their perspectives will help strengthen our governance and support long-term value creation for our stakeholders.”

Jill DeSimone, Independent Director, Indegene, said, “Life sciences organizations are navigating increasing scientific complexity and higher expectations across the product lifecycle. Indegene’s practitioner-led, technology-enabled approach positions it well to support this evolution. I am eager to partner with the leadership team to help strengthen the company’s impact across the commercialization value chain.”

Neeraj Bharadwaj, Independent Director, Indegene, said, “Indegene has built a differentiated, tech-native organization by integrating deep life sciences expertise with contextualized technology and operational excellence. I look forward to supporting the company’s sustained growth and disciplined value creation.”

Indegene Limited (BSE: 544172, NSE: INDGN) is the tech-native, life sciences specialist orchestrating the path from commercialization strategy through execution. Trusted by the world’s top 20 biopharma companies across the value chain - from clinical and medical through commercial - Indegene helps life sciences leaders move at the speed of their ambition with #PractitionerLevelConfidence. Indegene’s difference comes from integrating deep domain knowledge, contextualized technology and operational excellence, built over 25 years. When bold life sciences leaders want to take breakthrough therapies to market faster, maximize impact, and create seamless experiences for patients and physicians, they count on Indegene. Orchestrate your path at www.indegene.com